Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique
about
Virulence factors of medically important fungiExperimental modulation of capsule size in Cryptococcus neoformansCapsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cellsCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice.Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune responseMobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen.T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and DSpleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge.Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in miceTransfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice.In vitro interactions of immune lymphocytes and Cryptococcus neoformans.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceRequirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice.Cryptococcus neoformans induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta in human microglia: role of specific antibody and soluble capsular polysaccharide.Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans.CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune responseResponse of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection.Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosisSkin testing of guinea pigs and footpad testing of mice with a new antigen for detecting delayed hypersensitivity to Cryptococcus neoformansImmunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3Fcgamma receptor I- and III-mediated macrophage inflammatory protein 1alpha induction in primary human and murine microgliaImmune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsivenessDelayed-type hypersensitivity responses in infected mice elicited by cytoplasmic fractions of Cryptococcus neoformansRegulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity.Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodiesEffects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation.Murine natural killer cell interactions with a fungal target, Cryptococcus neoformansMonoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformansProduction of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages
P2860
Q24683790-2A90BB7C-40D0-4529-AFC2-E01F20FB3733Q24805267-DF3A1A5F-9115-41D3-896D-B3970EB1E575Q28478860-46919CDE-E0F5-4DD9-885D-3330DB389B45Q30424017-426F1A1D-3741-4066-A686-54600B9DE8BFQ30944228-EDAD0873-A0F4-4813-9CF1-FD4A28E227D3Q33602419-4CC6DED5-BB6B-4ACB-8C2A-F5B99D87D1FBQ33614286-2A9F98B3-2B44-41D6-877D-300B3D779BEEQ33616470-3CD7B6EA-C791-480D-A809-D7444101615BQ33619785-08DC964B-E9C5-4732-A357-269913BE92ADQ33674974-25E55EFB-B709-41E3-8F29-587E7B07B608Q33687443-17036F3C-3BA6-400E-945B-FA2147AAFD9CQ33751411-5734F241-844F-4606-8C91-0F49E9BBA04AQ33751838-AA3A3A79-B7AB-4666-8C54-97699852B1B3Q33760358-6DD312C5-3819-4E35-9AB9-40A034B8A4E5Q33762293-475FBCCB-6E70-45E7-B0E2-1AD7750547CAQ33857658-4726E8D5-944B-40AD-88F2-5780EA643EE4Q33906829-1C7A9F38-4A0A-46BF-A109-CDE391B31E3CQ33908408-AE186583-6637-4966-8974-AB2782847DC7Q33912930-EB680ED7-0D9B-462F-A31D-C9187B3E9C5DQ34001701-4E8DA785-A107-4BD2-8D9A-8C8448A08C15Q34003156-E6AFC85E-26CE-4D77-B044-F7D545B6B0D4Q34006498-F7C62B29-3FE3-45E1-817F-D0D78A5200A1Q34007117-995252B2-7D40-4020-A7E2-07487564AE20Q34007765-08FFD867-2C3E-4312-B1CF-025F1429CEC4Q34079721-9FE4A2AB-F44E-4FD9-95CC-671FB8713AD4Q34088703-070AEA82-AB7C-4F59-9DE0-F42576B41118Q34104354-87B21A99-731A-4893-ADB2-BA8A5001CEAEQ34121516-69CDA4C0-2E42-4434-9224-F0611F1740C1Q34130404-3F28BC70-05FD-4933-8A3D-C707EA338649Q34420549-6B20B704-5C44-45D4-AB8A-E54F8F5CBBF8Q34456966-F1A926B4-162A-428B-B217-49AE2E080E6EQ34530361-3E5C2E10-A720-4C9C-BE1E-98910BF1E278Q34561087-F157B025-8DE2-4475-AF37-8AFE0DE2504FQ34757345-9E3B89D5-6B32-4F07-85B5-E1843E2C9502Q35094163-B5D396F5-2E1B-4FE9-92C8-93222F047238Q35111117-1DC1A135-6575-4069-A51F-7BE8B208E3A9Q35115708-5E9FE0D6-2CA5-4918-AB8D-A7EC95CA8836Q35197055-5C1F43DD-433A-4791-9079-E0AEDF768A9BQ35225603-E5D8F991-DB1D-44C6-8883-7BC9EA9208B6Q35386000-3A72CE50-1600-43B6-9B98-09206D8B7510
P2860
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique
description
1972 nî lūn-bûn
@nan
1972 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Immunological unresponsiveness ...... the hemolytic plaque technique
@ast
Immunological unresponsiveness ...... the hemolytic plaque technique
@en
Immunological unresponsiveness ...... the hemolytic plaque technique
@nl
type
label
Immunological unresponsiveness ...... the hemolytic plaque technique
@ast
Immunological unresponsiveness ...... the hemolytic plaque technique
@en
Immunological unresponsiveness ...... the hemolytic plaque technique
@nl
prefLabel
Immunological unresponsiveness ...... the hemolytic plaque technique
@ast
Immunological unresponsiveness ...... the hemolytic plaque technique
@en
Immunological unresponsiveness ...... the hemolytic plaque technique
@nl
P2860
P1476
Immunological unresponsiveness ...... the hemolytic plaque technique
@en
P2093
P2860
P304
P407
P577
1972-06-01T00:00:00Z